Who
Laura Lee Sandler
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Oruka Therapeutics.
In numbers
- Trades disclosed
- 63
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $3.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jul 2025
- Last trade
- 15 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Dec 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $87K906 at $95.71 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $87K906 at $95.71 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $39K5,000 at $7.80 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K1,000 at $91.05 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $368K4,000 at $92.01 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $39K5,000 at $7.80 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K1,000 at $91.05 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $368K4,000 at $92.01 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $39K5,000 at $7.80 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $210K2,237 at $93.85 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $214K2,263 at $94.75 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K500 at $95.47 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $39K5,000 at $7.80 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $210K2,237 at $93.85 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $214K2,263 at $94.75 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K500 at $95.47 | filing |
News
No headline names them, or the companies they trade most, lately.